STOCK TITAN

Igm Biosciences, Inc. - IGMS STOCK NEWS

Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.

IGM Biosciences, Inc. (IGMS) is a clinical-stage biotechnology company pioneering IgM antibody therapeutics for cancer, autoimmune disorders, and inflammatory diseases. This page serves as the definitive source for official news, press releases, and financial updates directly from the company and verified partners.

Investors and stakeholders will find timely updates on clinical trial milestones, regulatory developments, and strategic collaborations with global pharmaceutical leaders. The curated content includes earnings reports, research breakthroughs, and pipeline advancements related to the company’s proprietary IgM platform, which enables multispecific antibody engineering.

Bookmark this page to track IGM Biosciences’ progress in developing novel therapies that leverage the unique binding capabilities of IgM antibodies. Visit regularly for unfiltered access to critical updates that may impact long-term investment strategies and sector analysis.

Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) Announces Third IND Cleared for Imvotamab in Autoimmune Diseases and International Sites Opened for Aplitabart Randomized Clinical Trial. The company presents its financial results for the quarter ended September 30, 2023, highlighting progress in clinical development, pipeline products, and 2023 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
-
Rhea-AI Summary
Medivir AB (Nasdaq Stockholm: MVIR) announces the presentation of clinical data from the phase 1b/2a study of fostrox in combination with Lenvima at the ASCO Gastrointestinal Cancers Symposium. The FDA interactions for fostrox's clinical development plan have intensified, with a positive response for the planned phase 2b study design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
conferences clinical trial
-
Rhea-AI Summary
IGM Biosciences, Inc. (Nasdaq: IGMS) announced that CEO Fred Schwarzer will present at the Stifel Healthcare Conference on November 14 and the Jefferies London Healthcare Conference on November 16. The presentations will be available via live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.43%
Tags
conferences
Rhea-AI Summary
Medivir AB plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks. The data update will be part of Medivir's interim report for the third quarter on Friday, October 27, 2023, followed by a comprehensive update in a webcasted presentation at 14.00 CET the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences clinical trial
-
Rhea-AI Summary
Medivir AB announces appointment of nomination committee for Annual General Meeting in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
-
News
Rhea-AI Summary
Medivir AB board member Anette Lindqvist resigns due to personal reasons
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
management
Rhea-AI Summary
Medivir AB announces promising clinical benefit in ongoing phase 2a study for advanced hepatocellular carcinoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
none
-
Rhea-AI Summary
IGM Biosciences announces retirement of Dr. Michael Loberg from Board of Directors and appointment of Dr. Elizabeth H.Z. Thompson as new board member.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
management
-
Rhea-AI Summary
Medivir to present at the Pareto Securities Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
Rhea-AI Summary
Medivir's partner Tango Therapeutics receives FDA clearance for TNG348, a USP1 inhibitor for the treatment of HRD+ cancers. Phase 1/2 study to be initiated in 2024. Medivir entitled to milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
Igm Biosciences, Inc.

Nasdaq:IGMS

IGMS Rankings

IGMS Stock Data

72.93M
31.06M
38.81%
59.41%
1.93%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW